GenSight: Goldman Sachs exceeds 5%


(CercleFinance.com) – Goldman Sachs Group declared to the AMF that, on February 13, it had exceeded the thresholds of 5% of the capital and voting rights of GenSight Biologics and held, through Goldman Sachs International, 6 .80% of the capital and voting rights of this company.

This crossing of thresholds results from an off-market acquisition of GenSight Biologics shares and an increase in the number of shares held by assimilation. Goldman Sachs International has individually crossed the same thresholds upwards.

Copyright © 2024 CercleFinance.com. All rights reserved.

Did you like this article ? Share it with your friends using the buttons below.





Facebook


Linkedin


E-mail





Source link -85